Orca Bio to Showcase TREGZI™ and Pipeline Data at SOHO 2026
Event summary
- Orca Bio will present three clinical data updates at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO) from September 9-12, 2026.
- Presentations include data on TREGZI™, the company’s recently approved precision-engineered cell therapy for allogenic transplant in adults with hematologic malignancies.
- Additional updates will cover Orca Bio’s investigational allogeneic T-cell immunotherapy, Orca-Q®.
- One study, SERENE-T, will be published in Clinical Lymphoma, Myeloma and Leukemia as part of the SOHO 2026 meeting proceedings supplement.
The big picture
Orca Bio’s presentations at SOHO 2026 come at a critical juncture as the company seeks to solidify its position in the high-precision cell therapy market. The focus on TREGZI™, its recently approved therapy, and the investigational Orca-Q® highlights the company’s strategic push to expand its clinical pipeline and demonstrate the efficacy of its proprietary platform. The broader industry is watching closely as cell therapies gain traction in treating hematologic malignancies, with regulatory and commercial success hinging on robust clinical data.
What we're watching
- Clinical Validation
- How the data on TREGZI™ and Orca-Q® will influence investor confidence and potential partnerships.
- Regulatory Momentum
- Whether the positive data will accelerate the approval process for Orca-Q® and other pipeline candidates.
- Market Positioning
- The pace at which Orca Bio can differentiate itself in the competitive cell therapy landscape.
Related topics